• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cardlytics Announces First Quarter 2025 Financial Results

    5/7/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email

    Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025.

    "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers."

    "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Cardlytics. "With recent actions to strengthen our balance sheet, we're taking a targeted, disciplined approach to cost management while continuing to invest in key areas for growth."

    First Quarter 2025 Financial Results

    • Revenue was $61.9 million, a decrease of 8% year-over-year compared to $67.6 million in the first quarter of 2024.
    • Billings, a non-GAAP metric, was $97.6 million, a decrease of 7% year-over-year compared to $105.2 million in the first quarter of 2024.
    • Adjusted Contribution, a non-GAAP metric, was $32.4 million, a decrease of 12% year-over-year compared to $37.1 million in the first quarter of 2024.
    • Net Loss was $(13.3) million, or $(0.26) per diluted share, based on 51.9 million fully diluted weighted-average common shares, compared to a Net Loss of $(24.3) million, or $(0.56) per diluted share, based on 43.2 million fully diluted weighted-average common shares in the first quarter of 2024.
    • Adjusted EBITDA, a non-GAAP metric, was $(4.4) million compared to $0.2 million in the first quarter of 2024.
    • Adjusted Net Loss was $(11.1) million, or $(0.21) per diluted share, based on 51.9 million fully diluted weighted-average common shares, compared to Adjusted Net Loss of $(4.1) million, or $(0.09) per diluted share, based on 43.2 million fully diluted weighted-average common shares in the first quarter of 2024.
    • Net cash used in operating activities was $(6.7) million, compared to $(17.6) million in the first quarter of 2024.
    • Free Cash Flow, a non-GAAP metric, was $(10.8) million, compared to $(22.4) million in the first quarter of 2024.

    Key Metrics

    • Cardlytics monthly qualified users ("MQUs") were 214.9 million, an increase of 12% year-over-year, compared to 191.2 million in the first quarter of 2024.
    • Cardlytics adjusted contribution per user ("ACPU") was $0.13 compared to $0.17 in the first quarter of 2024.

    Definitions of MQUs and ACPU are included below under the caption "Other Performance Metrics."

    The following table presents MQUs for the historical periods indicated:

     

    Three Months Ended

    in thousands

    March 31, 2023

     

    June 30, 2023

     

    September 30, 2023

     

    December 31, 2023

     

    March 31, 2024

     

    June 30, 2024

     

    September 30, 2024

     

    December 31, 2024

    Cardlytics MQUs

    181,720

     

    186,225

     

    189,126

     

    191,865

     

    191,206

     

    188,816

     

    190,233

     

    191,674

    The following table presents ACPU for the historical periods indicated:

     

    Three Months Ended

     

    March 31, 2023

     

    June 30, 2023

     

    September 30, 2023

     

    December 31, 2023

     

    March 31, 2024

     

    June 30, 2024

     

    September 30, 2024

     

    December 31, 2024

    Cardlytics ACPU

    $

    0.14

     

    $

    0.17

     

    $

    0.20

     

    $

    0.21

     

    $

    0.17

     

    $

    0.16

     

    $

    0.16

     

    $

    0.18

    CARDLYTICS, INC.

    SUMMARY OF GAAP AND NON-GAAP RESULTS (UNAUDITED)

    (Dollars in thousands)

     

     

    Three Months Ended

    March 31,

     

     

     

     

    2025

     

     

     

    2024

     

     

    Change %

    Billings(1)

    $

    97,579

     

     

    $

    105,216

     

     

    (7

    )%

    Consumer Incentives

     

    35,681

     

     

     

    37,608

     

     

    (5

    )%

    Revenue

     

    61,898

     

     

     

    67,608

     

     

    (8

    )%

    Partner Share and other third-party costs

     

    29,450

     

     

     

    30,543

     

     

    (4

    )%

    Adjusted Contribution(1)

     

    32,448

     

     

     

    37,065

     

     

    (12

    )%

    Delivery costs

     

    7,288

     

     

     

    6,173

     

     

    18

    %

    Gross Profit

    $

    25,160

     

     

    $

    30,892

     

     

    (19

    )%

    Net Loss

    $

    (13,282

    )

     

    $

    (24,275

    )

     

    (45

    )%

    Adjusted EBITDA(1)

    $

    (4,384

    )

     

    $

    226

     

     

    na

     

     

     

     

     

     

    Adjusted Contribution

     

     

     

     

     

    % of Billings

     

    33.3

    %

     

     

    35.2

    %

     

     

    % of Revenue

     

    52.4

    %

     

     

    54.8

    %

     

     

    Adjusted EBITDA

     

     

     

     

     

    % of Billings

     

    (4.5

    )%

     

     

    0.2

    %

     

     

    % of Revenue

     

    (7.1

    )%

     

     

    0.3

    %

     

     

    (1)

    Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

    Second Quarter 2025 Financial Expectations

    Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates):

     

    Q2 2025

    Guidance

     

    YoY Change

    Billings(1)

    $100.0 - 108.0

     

    (9%) - (2%)

    Revenue

    $61.0 - $67.0

     

    (12%) - (4%)

    Adjusted Contribution(2)

    $32.5 - $36.5

     

    (11%) - 0%

    Adjusted EBITDA(2)

    ($4.0) - $1.0

     

    ($1.7) - $3.3

    (1)

    A reconciliation of Billings to GAAP Revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."

    (2)

    A reconciliation of Adjusted Contribution to GAAP Gross Profit and a reconciliation of Adjusted EBITDA to Net Loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

    Earnings Teleconference Information

    Cardlytics will discuss its first quarter 2025 financial results during a live audio webcast today, May 7, 2025, at 5:00 PM ET / 2:00 PM PT. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics' website.

    About Cardlytics

    Cardlytics (NASDAQ:CDLX) is a digital advertising platform. We partner with financial institutions to run their rewards programs that promote customer loyalty and deepen relationships. In turn, we have a secure view into approximately 1 of every 2 card-based transactions in the U.S., allowing us to see where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in Menlo Park, Los Angeles, New York, and London. Learn more at www.cardlytics.com.

    Cautionary Language Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to our strategic initiatives to strengthen our business and market position and our financial guidance for the second quarter of 2025. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

    Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions, including, but not limited to, inflationary pressure or the imposition of tariffs and other trade protection measures, in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association ("Chase"), Bank of America, National Association ("Bank of America"), Wells Fargo Bank, National Association ("Wells Fargo"), American Express Travel Related Services Company, Inc. ("American Express") and a limited number of other financial institution ("FI") partners; risks related to our ability to maintain relationships with Chase, Wells Fargo and Bank of America; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors; our ability to generate sufficient revenue to offset contractual commitments to FI partners; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; risks related to our competitive market, including our ability to compete successfully with our current or future competitors; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; and other risks detailed in the "Risk Factors" section of our Form 10-Q filed with the Securities and Exchange Commission on May 7, 2025 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

    The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Non-GAAP Measures and Other Performance Metrics

    To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of financial performance in this press release: Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss, Adjusted Net Loss per share and Free Cash Flow, as well as certain other performance metrics, such as MQUs and ACPU.

    A "non-GAAP financial measure" refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.

    We have presented Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss and Adjusted Net Loss per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform Billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP Revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform Billings is the same as Bridg platform GAAP Revenue. Adjusted Contribution measures the degree by which Revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted Contribution demonstrates how incremental Revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administrative and other investments. Adjusted Contribution is calculated by taking our total Revenue less our Partner Share and other third-party costs. Adjusted Contribution does not take into account all costs associated with generating Revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. Management views Adjusted Contribution as the most relevant metric to measure the financial performance as it reflects the dollars we keep after all of our partners are paid. Adjusted EBITDA represents our Net Loss before interest expense, net; depreciation and amortization; stock-based compensation expense; foreign currency (gain) loss; loss (gain) on disposal or divestiture; and change in contingent consideration; and, in applicable periods, certain other income and expense items, such as impairment of goodwill and intangible assets; gain on debt extinguishment; acquisition, integration and divestiture costs (benefit); restructuring and reduction of force; income tax benefit; and deferred implementation costs. Adjusted Net Loss as our Net Loss before stock-based compensation expense; foreign currency (gain) loss; amortization of acquired intangibles; loss (gain) on disposal or divestiture; change in contingent consideration; and, in applicable periods, certain other income and expense items, such as gain on debt extinguishment; acquisition, integration and divestiture costs (benefit); restructuring and reduction of force; impairment of goodwill and intangible assets and income tax benefit. We define Adjusted Net Loss per share as Adjusted Net Loss divided by our weighted-average common shares outstanding, diluted. We define Free Cash Flow as net cash used in operating activities, plus acquisition of property and equipment and capitalized software development costs and, in applicable periods, acquisition of patents. We believe free cash flow is useful to measure the funds generated in a given period that are available for distribution or to sustain the business. We believe this supplemental information enhances stockholders' ability to evaluate our performance.

    We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance.

    We define MQUs as targetable customers that have made a transaction using their account with an FI Partner or non-FI Partner in a given month, excluding pilot supply during the ramp up period, and whose transaction data was shared with Cardlytics. We then calculate a monthly average of these MQUs for the periods presented. We believe that the number of MQUs is an indicator of the Cardlytics platform's ability to drive engagement and is reflective of the consumer base and insights that we offer to marketers. As of January 1, 2025, we will no longer report Cardlytics Monthly Active Users given we do not receive equivalent user data from our newer bank partners. We define ACPU as the Cardlytics platform Adjusted Contribution generated in the applicable period, divided by Cardlytics average MQUs in the applicable period. We believe that Adjusted Contribution is the most relevant metric as it reflects the value Cardlytics keeps after subtracting out rewards, Partner Share and other third-party costs. We believe that ACPU measures the Cardlytics platform's efficiency in converting marketer budgets into the value generated by customer engagement. Beginning on March 31, 2025, we will no longer report Cardlytics Average Revenue per User.

    CARDLYTICS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

    (Amounts in thousands, except par value amounts)

     

     

    March 31,

    2025

     

    December 31,

    2024

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    52,046

     

     

    $

    65,594

     

    Accounts receivable and contract assets, net

     

    96,094

     

     

     

    103,252

     

    Other receivables

     

    3,358

     

     

     

    3,801

     

    Prepaid expenses and other assets

     

    5,331

     

     

     

    5,336

     

    Total current assets

     

    156,829

     

     

     

    177,983

     

    Long-term assets:

     

     

     

    Property and equipment, net

     

    2,466

     

     

     

    2,596

     

    Right-of-use assets under operating leases, net

     

    5,062

     

     

     

    6,341

     

    Intangible assets, net

     

    9,916

     

     

     

    11,371

     

    Goodwill

     

    159,429

     

     

     

    159,429

     

    Capitalized software development costs, net

     

    33,867

     

     

     

    33,341

     

    Other long-term assets, net

     

    1,504

     

     

     

    1,650

     

    Total assets

    $

    369,073

     

     

    $

    392,711

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    4,445

     

     

    $

    3,689

     

    Accrued liabilities:

     

     

     

    Accrued compensation

     

    6,442

     

     

     

    5,494

     

    Accrued expenses

     

    8,378

     

     

     

    7,175

     

    Partner Share liability

     

    28,759

     

     

     

    32,479

     

    Consumer Incentive liability

     

    31,800

     

     

     

    45,513

     

    Short-term debt

     

    45,936

     

     

     

    45,863

     

    Deferred revenue

     

    2,608

     

     

     

    2,154

     

    Current operating lease liabilities

     

    1,658

     

     

     

    2,025

     

    Current contingent consideration

     

    1,825

     

     

     

    4,563

     

    Total current liabilities

     

    131,851

     

     

     

    148,955

     

    Long-term liabilities:

     

     

     

    Convertible senior notes, net

     

    168,009

     

     

     

    167,729

     

    Long-term operating lease liabilities

     

    5,123

     

     

     

    6,034

     

    Total liabilities

    $

    304,983

     

     

    $

    322,718

     

    Stockholders' equity:

     

     

     

    Common stock, $0.0001 par value—100,000 shares authorized, 52,175 and 51,257 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively

    $

    10

     

     

    $

    10

     

    Additional paid-in capital

     

    1,376,692

     

     

     

    1,366,958

     

    Accumulated other comprehensive income

     

    1,246

     

     

     

    3,601

     

    Accumulated deficit

     

    (1,313,858

    )

     

     

    (1,300,576

    )

    Total stockholders' equity

     

    64,090

     

     

     

    69,993

     

    Total liabilities and stockholders' equity

    $

    369,073

     

     

    $

    392,711

     

    CARDLYTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

    (Amounts in thousands, except per share amounts)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

    Revenue

    $

    61,898

     

     

    $

    67,608

     

    Costs and expenses:

     

     

     

    Partner Share and other third-party costs

     

    29,450

     

     

     

    30,543

     

    Delivery costs

     

    7,288

     

     

     

    6,173

     

    Sales and marketing expense

     

    12,754

     

     

     

    14,118

     

    Research and development expense

     

    11,706

     

     

     

    13,048

     

    General and administrative expense

     

    13,778

     

     

     

    14,485

     

    Change in contingent consideration

     

    60

     

     

     

    5,817

     

    Loss (gain) on disposal or divestiture

     

    (5,350

    )

     

     

    —

     

    Depreciation and amortization expense

     

    6,291

     

     

     

    6,250

     

    Total costs and expenses

     

    75,977

     

     

     

    90,434

     

    Operating Loss

     

    (14,079

    )

     

     

    (22,826

    )

    Other income (expense):

     

     

     

    Interest expense, net

     

    (1,830

    )

     

     

    (819

    )

    Foreign currency gain (loss)

     

    2,627

     

     

     

    (630

    )

    Total other income (expense)

     

    797

     

     

     

    (1,449

    )

    Loss before income taxes

     

    (13,282

    )

     

     

    (24,275

    )

    Net Loss

    $

    (13,282

    )

     

    $

    (24,275

    )

    Net Loss per share, basic and diluted

    $

    (0.26

    )

     

    $

    (0.56

    )

    Weighted-average common shares outstanding, basic and diluted

     

    51,863

     

     

     

    43,248

     

    CARDLYTICS, INC.

    STOCK-BASED COMPENSATION EXPENSE (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

    2024

    Delivery costs

    $

    537

     

    $

    643

    Sales and marketing expense

     

    2,078

     

     

    3,141

    Research and development expense

     

    2,774

     

     

    3,950

    General and administrative expense

     

    3,305

     

     

    3,251

    Total stock-based compensation expense

    $

    8,694

     

    $

    10,985

    CARDLYTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

    Operating activities

     

     

     

    Net Loss

    $

    (13,282

    )

     

    $

    (24,275

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Credit loss expense

     

    643

     

     

     

    1,570

     

    Depreciation and amortization

     

    6,291

     

     

     

    6,250

     

    Amortization of financing costs charged to interest expense

     

    405

     

     

     

    445

     

    Amortization of right-of-use assets

     

    632

     

     

     

    549

     

    Loss (gain) on disposal or divestiture

     

    (5,350

    )

     

     

    —

     

    Stock-based compensation expense

     

    8,694

     

     

     

    10,985

     

    Change in contingent consideration

     

    60

     

     

     

    5,817

     

    Other non-cash (income) expense, net

     

    (2,620

    )

     

     

    667

     

    Change in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    7,536

     

     

     

    13,323

     

    Prepaid expenses and other assets

     

    (56

    )

     

     

    (3,450

    )

    Accounts payable

     

    551

     

     

     

    125

     

    Other accrued expenses

     

    1,895

     

     

     

    (7,634

    )

    Partner Share liability

     

    (3,860

    )

     

     

    (13,291

    )

    Consumer Incentive liability

     

    (8,245

    )

     

     

    (8,698

    )

    Net cash used in operating activities

     

    (6,706

    )

     

     

    (17,617

    )

    Investing activities

     

     

     

    Acquisition of property and equipment

     

    (119

    )

     

     

    (651

    )

    Capitalized software development costs

     

    (3,984

    )

     

     

    (4,096

    )

    Business divestiture

     

    200

     

     

     

    —

     

    Net cash used in investing activities

     

    (3,903

    )

     

     

    (4,747

    )

    Financing activities

     

     

     

    Settlement of contingent consideration

     

    (3,000

    )

     

     

    (20,074

    )

    Proceeds from issuance of common stock

     

    —

     

     

     

    48,634

     

    Debt issuance costs

     

    (34

    )

     

     

    (239

    )

    Net cash (used in) provided by financing activities

     

    (3,034

    )

     

     

    28,321

     

    Effect of exchange rates on cash and cash equivalents

     

    95

     

     

     

    (21

    )

    Net (decrease) increase in cash and cash equivalents

     

    (13,548

    )

     

     

    5,936

     

    Cash and cash equivalents — Beginning of period

     

    65,594

     

     

     

    91,830

     

    Cash and cash equivalents — End of period

    $

    52,046

     

     

    $

    97,766

     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP REVENUE TO BILLINGS (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

    2024

    Consolidated

     

     

     

    Revenue

    $

    61,898

     

    $

    67,608

    Plus:

     

     

     

    Consumer Incentives

     

    35,681

     

     

    37,608

    Billings

    $

    97,579

     

    $

    105,216

    Cardlytics platform

     

     

     

    Revenue

    $

    56,435

     

    $

    62,233

    Plus:

     

     

     

    Consumer Incentives

     

    35,681

     

     

    37,608

    Billings

    $

    92,116

     

    $

    99,841

    Bridg platform

     

     

     

    Revenue

    $

    5,463

     

    $

    5,375

    Plus:

     

     

     

    Consumer Incentives

     

    —

     

     

    —

    Billings

    $

    5,463

     

    $

    5,375

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

    2024

    Revenue

    $

    61,898

     

    $

    67,608

    Minus:

     

     

     

    Partner Share and other third-party costs

     

    29,450

     

     

    30,543

    Delivery costs(1)

     

    7,288

     

     

    6,173

    Gross Profit

     

    25,160

     

     

    30,892

    Plus:

     

     

     

    Delivery costs(1)

     

    7,288

     

     

    6,173

    Adjusted Contribution

    $

    32,448

     

    $

    37,065

    (1)

    Stock-based compensation expense recognized in consolidated delivery costs totaled $0.5 million and $0.6 million during the three months ended March 31, 2025 and 2024, respectively.

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

    Net Loss

    $

    (13,282

    )

     

    $

    (24,275

    )

    Plus:

     

     

     

    Interest expense, net

     

    1,830

     

     

     

    819

     

    Depreciation and amortization

     

    6,291

     

     

     

    6,250

     

    Stock-based compensation expense

     

    8,694

     

     

     

    10,985

     

    Foreign currency (gain) loss

     

    (2,627

    )

     

     

    630

     

    Loss (gain) on disposal or divestiture

     

    (5,350

    )

     

     

    —

     

    Change in contingent consideration

     

    60

     

     

     

    5,817

     

    Adjusted EBITDA

    $

    (4,384

    )

     

    $

    226

     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED NET LOSS

    AND ADJUSTED NET LOSS PER SHARE (UNAUDITED)

    (Amounts in thousands, except per share amounts)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

    Net Loss

    $

    (13,282

    )

     

    $

    (24,275

    )

    Plus:

     

     

     

    Stock-based compensation expense

     

    8,694

     

     

     

    10,985

     

    Foreign currency (gain) loss

     

    (2,627

    )

     

     

    630

     

    Amortization of acquired intangibles

     

    1,455

     

     

     

    2,789

     

    Loss (gain) on disposal or divestiture

     

    (5,350

    )

     

     

    —

     

    Change in contingent consideration

     

    60

     

     

     

    5,817

     

    Adjusted Net Loss

    $

    (11,050

    )

     

    $

    (4,054

    )

    Weighted-average number of shares of common stock used in computing Adjusted Net Loss per share:

     

     

     

    Weighted-average common shares outstanding, diluted

     

    51,863

     

     

     

    43,248

     

    Adjusted Net Loss per share, diluted

    $

    (0.21

    )

     

    $

    (0.09

    )

    CARDLYTICS, INC.

    RECONCILIATION OF NET CASH USED IN OPERATING ACTIVITIES TO FREE CASH FLOW (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

    Net cash used in operating activities

    $

    (6,706

    )

     

    $

    (17,617

    )

    Plus:

     

     

     

    Acquisition of property and equipment

     

    (119

    )

     

     

    (651

    )

    Capitalized software development costs

     

    (3,984

    )

     

     

    (4,096

    )

    Free Cash Flow

    $

    (10,809

    )

     

    $

    (22,364

    )

    CARDLYTICS, INC.

    RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS (UNAUDITED)

    (Amounts in thousands)

     

     

    Q2 2025

    Revenue

    $61.0 - $67.0

    Plus:

     

    Consumer Incentives

    $33.0 - $47.0

    Billings

    $100.0 - 108.0

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507247318/en/

    Public Relations:

    [email protected]

    Investor Relations:

    [email protected]

    Get the next $CDLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Financials

    Live finance-specific insights

    See more
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Timing of Its First Quarter 2025 Earnings Release

      Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2025 will be released on May 7, 2025, after market close. Conference Call Details: When: May 7, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 86123. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that

      4/23/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024. "While 2024 was a challenging year for Cardlytics, we nevertheless planted the seeds and refocused our efforts to get back on track for growth this year," said Amit Gupta, CEO of Cardlytics. "We remain grounded in our vision for long-term and sustainable growth. We are focused on strengthening our competitive moat through our efforts to modernize our platform, enhance our product and tech capabilities, and expand our network of partners and advertisers." "In 2025, we are focused on delivering sequential improvements and positive Adjusted EBITDA," said Alexis DeSie

      3/12/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

      Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

      4/30/25 9:00:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Cardlytics, Inc. (NASDAQ:CDLX) today announced that on April 24, 2025, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 124,050 restricted stock units of Cardlytics to 11 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). For all of the grant recipients, 50% of the restricted stock units shall vest on the first anniversary of the grant date, and the remaining 50% shall vest quarterly over the subsequent 12 months, subject to the employees' continu

      4/25/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cardlytics Inc.

      10-Q - Cardlytics, Inc. (0001666071) (Filer)

      5/7/25 4:30:52 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cardlytics, Inc. (0001666071) (Filer)

      5/7/25 4:07:09 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form DEFR14A filed by Cardlytics Inc.

      DEFR14A - Cardlytics, Inc. (0001666071) (Filer)

      4/29/25 4:02:21 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:46:37 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:45:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:39:19 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    See more

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

      Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

      4/30/25 9:00:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Cardlytics Appoints Amit Gupta as CEO

      ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced that the Board of Directors has appointed Amit Gupta, Chief Operating Officer and General Manager of Bridg, as its next Chief Executive Officer of Cardlytics, effective August 16, 2024. He will also join the Cardlytics Board of Directors on that date. Mr. Gupta will succeed Karim Temsamani, who is stepping down as Chief Executive Officer and from the Board of Directors to pursue another professional opportunity. "Amit is the right person to lead Cardlytics in its next stage of growth," said Jack Klinck, Chair of the Cardlytics Board. "For the last year and a half, Ami

      8/7/24 4:10:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer converted options into 682 shares and sold $458 worth of shares (303 units at $1.51), increasing direct ownership by 0.37% to 102,119 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      4/22/25 8:27:13 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Hornsey Liane converted options into 1,326 shares, increasing direct ownership by 13% to 11,326 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      4/9/25 4:04:33 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Chief Executive Officer Gupta Amit converted options into 14,350 shares and sold $13,260 worth of shares (7,342 units at $1.81), increasing direct ownership by 2% to 371,080 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      4/3/25 4:12:45 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      7/2/24 7:05:14 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      3/29/24 5:05:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      3/18/24 7:46:57 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Evercore ISI initiated coverage on Cardlytics with a new price target

      Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

      10/11/24 8:36:58 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by Northland Capital with a new price target

      Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

      8/16/24 8:54:02 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

      8/15/24 7:18:52 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology